131 related articles for article (PubMed ID: 16918349)
1. Isoniazid is not a lead compound for its pyridyl ring derivatives, isonicotinoyl amides, hydrazides, and hydrazones: a critical review.
Scior T; Garcés-Eisele SJ
Curr Med Chem; 2006; 13(18):2205-19. PubMed ID: 16918349
[TBL] [Abstract][Full Text] [Related]
2. Potent antimycobacterial activity of the pyridoxal isonicotinoyl hydrazone analog 2-pyridylcarboxaldehyde isonicotinoyl hydrazone: a lipophilic transport vehicle for isonicotinic acid hydrazide.
Ellis S; Kalinowski DS; Leotta L; Huang ML; Jelfs P; Sintchenko V; Richardson DR; Triccas JA
Mol Pharmacol; 2014 Feb; 85(2):269-78. PubMed ID: 24243647
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity.
Martins F; Santos S; Ventura C; Elvas-Leitão R; Santos L; Vitorino S; Reis M; Miranda V; Correia HF; Aires-de-Sousa J; Kovalishyn V; Latino DA; Ramos J; Viveiros M
Eur J Med Chem; 2014 Jun; 81():119-38. PubMed ID: 24836065
[TBL] [Abstract][Full Text] [Related]
4. The Introduction of Hydrazone, Hydrazide, or Azepane Moieties to the Triterpenoid Core Enhances an Activity Against
Kazakova OB; Medvedeva NI; Smirnova IE; Lopatina TV; Veselovsky AV
Med Chem; 2021; 17(2):134-145. PubMed ID: 31939731
[TBL] [Abstract][Full Text] [Related]
5. Reinvestigation of the structure-activity relationships of isoniazid.
Hegde P; Boshoff HIM; Rusman Y; Aragaw WW; Salomon CE; Dick T; Aldrich CC
Tuberculosis (Edinb); 2021 Jul; 129():102100. PubMed ID: 34116482
[TBL] [Abstract][Full Text] [Related]
6. Designing new antitubercular isoniazid derivatives with improved reactivity and membrane trafficking abilities.
de Faria CF; Moreira T; Lopes P; Costa H; Krewall JR; Barton CM; Santos S; Goodwin D; Machado D; Viveiros M; Machuqueiro M; Martins F
Biomed Pharmacother; 2021 Dec; 144():112362. PubMed ID: 34710838
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of graphical invariants in quantitative structure-activity correlations of tuberculostatic drugs of the isonicotinic acid hydrazide type.
Bagchi MC; Maiti BC; Mills D; Basak SC
J Mol Model; 2004 Apr; 10(2):102-11. PubMed ID: 14691675
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and mechanistic investigation of iron(II) complexes of isoniazid and derivatives as a redox-mediated activation strategy for anti-tuberculosis therapy.
Laborde J; Deraeve C; de Mesquita Vieira FG; Sournia-Saquet A; Rechignat L; Villela AD; Abbadi BL; Macchi FS; Pissinate K; Bizarro CV; Machado P; Basso LA; Pratviel G; de França Lopes LG; Sousa EHS; Bernardes-Génisson V
J Inorg Biochem; 2018 Feb; 179():71-81. PubMed ID: 29175704
[TBL] [Abstract][Full Text] [Related]
9. In vitro advanced antimycobacterial screening of isoniazid-related hydrazones, hydrazides and cyanoboranes: part 14.
Maccari R; Ottanà R; Vigorita MG
Bioorg Med Chem Lett; 2005 May; 15(10):2509-13. PubMed ID: 15863306
[TBL] [Abstract][Full Text] [Related]
10. Application of quantitative structure-activity relationships to the modeling of antitubercular compounds. 1. The hydrazide family.
Ventura C; Martins F
J Med Chem; 2008 Feb; 51(3):612-24. PubMed ID: 18176999
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and antimycobacterial activity of isoniazid derivatives from renewable fatty acids.
Rodrigues MO; Cantos JB; D'Oca CR; Soares KL; Coelho TS; Piovesan LA; Russowsky D; da Silva PA; D'Oca MG
Bioorg Med Chem; 2013 Nov; 21(22):6910-4. PubMed ID: 24103427
[TBL] [Abstract][Full Text] [Related]
12. Isoniazid derivatives and their anti-tubercular activity.
Hu YQ; Zhang S; Zhao F; Gao C; Feng LS; Lv ZS; Xu Z; Wu X
Eur J Med Chem; 2017 Jun; 133():255-267. PubMed ID: 28390957
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and Antimycobacterial Activity of Isoniazid Derivatives Tethered with Aliphatic Amines.
Pflégr V; Stolaříková J; Vinšová J; Krátký M
Curr Top Med Chem; 2022; 22(32):2695-2706. PubMed ID: 35929626
[TBL] [Abstract][Full Text] [Related]
14. Insights on the Mechanism of Action of INH-C
Vila-Viçosa D; Victor BL; Ramos J; Machado D; Viveiros M; Switala J; Loewen PC; Leitão R; Martins F; Machuqueiro M
Mol Pharm; 2017 Dec; 14(12):4597-4605. PubMed ID: 29091448
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and in vitro antimycobacterial activity of 3-substituted 5-hydroxy-5-trifluoro[chloro]methyl-4,5-dihydro-1H-1-(isonicotinoyl) pyrazoles.
Almeida da Silva PE; Ramos DF; Bonacorso HG; de la Iglesia AI; Oliveira MR; Coelho T; Navarini J; Morbidoni HR; Zanatta N; Martins MA
Int J Antimicrob Agents; 2008 Aug; 32(2):139-44. PubMed ID: 18571384
[TBL] [Abstract][Full Text] [Related]
16. New series of isoniazid hydrazones linked with electron-withdrawing substituents.
Vavříková E; Polanc S; Kočevar M; Košmrlj J; Horváti K; Bosze S; Stolaříková J; Imramovský A; Vinšová J
Eur J Med Chem; 2011 Dec; 46(12):5902-9. PubMed ID: 22018878
[TBL] [Abstract][Full Text] [Related]
17. Study of mechanism of interaction of truncated isoniazid-nicotinamide adenine dinucleotide adduct against multiple enzymes of Mycobacterium tuberculosis by a computational approach.
Jena L; Deshmukh S; Waghmare P; Kumar S; Harinath BC
Int J Mycobacteriol; 2015 Dec; 4(4):276-83. PubMed ID: 26964808
[TBL] [Abstract][Full Text] [Related]
18. Peptide conjugates of therapeutically used antitubercular isoniazid-design, synthesis and antimycobacterial effect.
Horváti K; Mezo G; Szabó N; Hudecz F; Bosze S
J Pept Sci; 2009 May; 15(5):385-91. PubMed ID: 19319854
[TBL] [Abstract][Full Text] [Related]
19. Antimycobacterial activity of novel N-(substituted)-2-isonicotinoylhydrazinocarbothioamide endowed with high activity towards isoniazid resistant tuberculosis.
Sriram D; Yogeeswari P; Yelamanchili Priya D
Biomed Pharmacother; 2009 Jan; 63(1):36-9. PubMed ID: 18343086
[TBL] [Abstract][Full Text] [Related]
20. Mode of binding of the tuberculosis prodrug isoniazid to heme peroxidases: binding studies and crystal structure of bovine lactoperoxidase with isoniazid at 2.7 A resolution.
Singh AK; Kumar RP; Pandey N; Singh N; Sinha M; Bhushan A; Kaur P; Sharma S; Singh TP
J Biol Chem; 2010 Jan; 285(2):1569-76. PubMed ID: 19907057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
